AtriCure, Inc. Q1 2009 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2009. AtriCure, Inc. is a medical device company developing, manufacturing, and selling devices for the surgical ablation of cardiac tissue. The company operates as a single segment with sales in the United States and internationally. As of May 1, 2009, the company had 14,750,061 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenues | $13,673,903 | $13,530,145 |
| Gross Profit | $10,729,245 | $10,299,265 |
| Gross Margin | 78.5% | 76.1% |
| Net Loss | $(7,964,922) | $(3,605,435) |
| Loss Per Share (Basic/Diluted) | $(0.56) | $(0.25) |
| Cash and Cash Equivalents | $8,608,176 | $13,014,579 |
| Working Capital | $17,907,789 | $18,000,000 (approx) |
| Total Debt | $62,342 | $6,070,609 |
| Net Cash Used in Operating Activities | $(2,442,540) | $(3,828,482) |
Material Changes vs. Prior Period
- Goodwill Impairment: The company recorded a full goodwill impairment charge of $6,812,389 due to a reduction in market capitalization. This non-cash charge significantly increased the net loss compared to the prior year.
- Revenue Growth: Revenues increased 1.1% to $13.7 million, driven by increased unit sales in international markets, partially offset by a decline in U.S. unit sales and negative currency exchange impacts.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by $2.9 million (24%) primarily due to a reduction in force in Q4 2008. Research and development expenses increased by $0.5 million due to higher share-based compensation and clinical trial costs.
- Debt Repayment: The company repaid the full $6.0 million outstanding balance under its National City Bank credit facility during the quarter, reducing total debt significantly.
- Cash Flow: Net cash used in operating activities improved to $2.4 million from $3.8 million in the prior year, aided by the non-cash goodwill impairment and share-based compensation adjustments.
Outlook, Risks, and Contingencies
- New Credit Facility: On May 1, 2009, the company entered into a new agreement with Silicon Valley Bank providing a $10 million term loan (fully drawn at $6.5 million) and a $10 million revolving facility. The term loan bears 10% interest and includes a warrant for 371,732 shares.
- Liquidity: Management believes current cash, the new term loan proceeds, and operating cash flows will meet needs for at least the next 12 months.
- Legal Proceedings:
- DOJ Investigation: The Department of Justice is investigating potential False Claims Act violations regarding marketing practices and Medicare billing codes for atrial fibrillation treatment. Liability cannot be estimated.
- Class Action Lawsuits: Two active securities class action lawsuits allege violations of federal securities laws and improper promotion of products. The company intends to vigorously defend these claims.
- Goodwill Step 2: The company plans to complete the second step of the goodwill impairment analysis in Q2 2009, though a full impairment was already recognized based on Step 1.
Key Investor Verification Points
- Verify the status and potential financial impact of the ongoing Department of Justice investigation regarding billing practices.
- Monitor the company's ability to meet financial covenants under the new Silicon Valley Bank credit facility, specifically the minimum EBITDA and Adjusted Quick Ratio requirements.
- Assess the sustainability of revenue growth given the decline in U.S. unit sales and reliance on international markets.
- Review the progress of the goodwill impairment Step 2 analysis to confirm the final valuation of the reporting unit.
- Track the company's cash burn rate relative to its $8.6 million cash balance and new debt obligations.